GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » 1-Year ROIIC %

Biofrontera (Biofrontera) 1-Year ROIIC % : -102.33% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biofrontera 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Biofrontera's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was -102.33%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Biofrontera's 1-Year ROIIC % or its related term are showing as below:

BFRI's 1-Year ROIIC % is ranked worse than
84.95% of 1030 companies
in the Drug Manufacturers industry
Industry Median: 1.305 vs BFRI: -102.33

Biofrontera 1-Year ROIIC % Historical Data

The historical data trend for Biofrontera's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera 1-Year ROIIC % Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
- 529.65 -330.26 -115.19 8.97

Biofrontera Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.85 162.44 -226.05 8.97 -102.33

Competitive Comparison of Biofrontera's 1-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera's 1-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Biofrontera's 1-Year ROIIC % falls into.



Biofrontera 1-Year ROIIC % Calculation

Biofrontera's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -22.36 (Mar. 2024) - -24.9714 (Mar. 2023) )/( 13.444 (Mar. 2024) - 15.996 (Mar. 2023) )
=2.6114/-2.552
=-102.33%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Biofrontera  (NAS:BFRI) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Biofrontera 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Biofrontera's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera (Biofrontera) Business Description

Traded in Other Exchanges
N/A
Address
120 Presidential Way, Suite 330, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Executives
Heikki Lanckriet director C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler officer: Chief Financial Officer 84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber director 119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii director 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman director 5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge director 21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera 10 percent owner HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates officer: Controller C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco director, officer: Chief Financial Officer/COO C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert director, officer: Chief Executive Officer C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801